While Aclaris Therapeutics Inc has underperformed by -1.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACRS fell by -84.58%, with highs and lows ranging from $11.12 to $0.59, whereas the simple moving average fell by -73.69% in the last 200 days.
On January 22, 2024, H.C. Wainwright Downgraded Aclaris Therapeutics Inc (NASDAQ: ACRS) to Neutral. A report published by William Blair on November 13, 2023, Downgraded its rating to ‘Mkt Perform’ for ACRS. Evercore ISI also rated ACRS shares as ‘Outperform’, setting a target price of $22 on the company’s shares in an initiating report dated October 03, 2023. Stifel Initiated an Buy rating on December 14, 2022, and assigned a price target of $29. Goldman initiated its ‘Buy’ rating for ACRS, as published in its report on December 01, 2022. BTIG Research’s report from October 06, 2022 suggests a price prediction of $32 for ACRS shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Aclaris Therapeutics Inc (ACRS)
Further, the quarter-over-quarter increase in sales is 126.62%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Aclaris Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -49.88% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.16, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ACRS is recording an average volume of 1.77M. On a monthly basis, the volatility of the stock is set at 8.60%, whereas on a weekly basis, it is put at 5.72%, with a gain of 3.33% over the past seven days. Furthermore, long-term investors anticipate a median target price of $3.00, showing growth from the present price of $1.24, which can serve as yet another indication of whether ACRS is worth investing in or should be passed over.
How Do You Analyze Aclaris Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.09%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACRS shares are owned by institutional investors to the tune of 89.20% at present.
